About this Research Topic
Tumors evolve over the course of time and ongoing genomic studies provide guidance to oncologists regarding treatment options. Identification of genetic abnormalities in specific cancers have facilitated design of targeted therapies that frequently have dramatic positive effects. In addition to studies on blood to determine if specific germ line mutations are present, cancer genetics increasingly utilizes mutation analysis of tumors and there is a definite move toward “liquid biopsies”. Liquid biopsies, the analysis of cell free DNA in plasma and cerebrospinal fluid have been successfully used to determine treatment efficacy, and to reveal metastases and to analyze the mechanisms by which specific cancers become resistant to targeted therapies. Pre-prescription genetic information on a specific patient is particularly important when high- risk drugs are to be prescribed.
This Research Topic welcomes manuscripts that demonstrate advantages in specific cases of DNA sequencing for establishing disease diagnosis, defining possibilities for initiating therapies, and manuscripts dealing with the genetic counseling implications of DNA sequencing in patients. Manuscripts delineating use of nucleic acid sequencing in new approaches to point of care diagnostics are also welcomed.
Keywords: DNA, Sequencing, diagnosis, therapy, counselling
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.